Skip to main content
Erschienen in: Journal of Bone and Mineral Metabolism 1/2012

01.01.2012 | Case Report

Marked improvement of calcinosis in adult dermatomyositis with etidronate therapy

verfasst von: Hiroko Mori, Yosuke Okada, Kunihiro Yamaoka, Kazuyoshi Saito, Yoshiya Tanaka

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

We report a 26-year-old woman with severe calcinosis associated with dermatomyositis. Although calcinosis of the skin or muscles is unusual in adults with dermatomyositis, this patient developed subcutaneous calcinosis with tenderness on the arms, axillary areas, shoulder areas, chest, abdomen, pelvis, and limbs. The calcinosis steadily increased and spread until joint motions were severely limited. Radiographic examination showed extensive soft-tissue calcification with a reticular pattern and severe osteoporosis. The patient was treated with oral etidronate (800 mg/day for 3 months every 6 months) to prevent calcification of the lesions. Three months later, the patient showed a dramatic improvement in symptoms with softening of the calcinosis, reduced pain, and marked increase in joint mobility. Radiographic examination showed marked decreases in the size of the calcified lesions compared to pre-treatment findings, and this effect persisted with a constant progressive efficacy for 3 years. The 3-year course of etidronate therapy also resulted in marked improvement of the severe osteoporosis and the patient was able to return to work and enjoy a normal life. We propose etidronate as a beneficial and effective therapy for calcinosis with osteoporosis.
Literatur
2.
Zurück zum Zitat Mukamel M, Horev G, Mimouni M (2001) New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 138:763–766PubMedCrossRef Mukamel M, Horev G, Mimouni M (2001) New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 138:763–766PubMedCrossRef
3.
Zurück zum Zitat Oliveri MB, Palermo R, Mautalen C, Hubscher O (1996) Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol 23:2152–2155PubMed Oliveri MB, Palermo R, Mautalen C, Hubscher O (1996) Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol 23:2152–2155PubMed
4.
Zurück zum Zitat Ambler GR, Chaitow J, Rogers M, McDonald DW, Ouvrier RA (2005) Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 32:1837–1839PubMed Ambler GR, Chaitow J, Rogers M, McDonald DW, Ouvrier RA (2005) Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 32:1837–1839PubMed
5.
Zurück zum Zitat Landis WJ (1995) The strength of a calcified tissue depends in part on the molecular structure and organization of its constituent mineral crystals in their organic matrix. Bone 16:533–544PubMedCrossRef Landis WJ (1995) The strength of a calcified tissue depends in part on the molecular structure and organization of its constituent mineral crystals in their organic matrix. Bone 16:533–544PubMedCrossRef
6.
Zurück zum Zitat Wananukul S, Pongprasit P, Wattanakrai P (1997) Calcinosis cutis presenting years before other clinical manifestations of juvenile dermatomyositis: report of two cases. Australas J Dermatol 38:202–205PubMedCrossRef Wananukul S, Pongprasit P, Wattanakrai P (1997) Calcinosis cutis presenting years before other clinical manifestations of juvenile dermatomyositis: report of two cases. Australas J Dermatol 38:202–205PubMedCrossRef
7.
Zurück zum Zitat Rider L, Ahmed A, Beausang L, Zemel L, Rennebohn R, Packman L et al (1998) Elevations of interleukin-1 receptor antagonist (Il1RA), STNFR, SIL2R, and IL-10 in juvenile idiopathic inflammatory myopathies suggest a role for monocyte/macrophage and B lymphocyte anti-radium. Arthritis Rheum 41:S265CrossRef Rider L, Ahmed A, Beausang L, Zemel L, Rennebohn R, Packman L et al (1998) Elevations of interleukin-1 receptor antagonist (Il1RA), STNFR, SIL2R, and IL-10 in juvenile idiopathic inflammatory myopathies suggest a role for monocyte/macrophage and B lymphocyte anti-radium. Arthritis Rheum 41:S265CrossRef
8.
Zurück zum Zitat Bowyer SL, Blane CE, Sullivan DB, Cassidy JT (1983) Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 103:882–888PubMedCrossRef Bowyer SL, Blane CE, Sullivan DB, Cassidy JT (1983) Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 103:882–888PubMedCrossRef
9.
Zurück zum Zitat Pachman LM (1999) Myositis. In: Textbook of adolescent rheumatology, 1st edn. Martin Dunitz, London, UK, pp 127–146 Pachman LM (1999) Myositis. In: Textbook of adolescent rheumatology, 1st edn. Martin Dunitz, London, UK, pp 127–146
11.
Zurück zum Zitat Boulman N, Slobodin G, Rozenbaum M, Rosner I (2005) Calcinosis in rheumatic diseases. Semin Arthritis Rheum 34:805–812PubMedCrossRef Boulman N, Slobodin G, Rozenbaum M, Rosner I (2005) Calcinosis in rheumatic diseases. Semin Arthritis Rheum 34:805–812PubMedCrossRef
12.
Zurück zum Zitat Marco Puche A, Calvo Penades I, Lopez Montesinos B (2010) Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 28:135–140PubMed Marco Puche A, Calvo Penades I, Lopez Montesinos B (2010) Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 28:135–140PubMed
13.
Zurück zum Zitat Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A (2010) Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 77:70–72PubMedCrossRef Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A (2010) Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 77:70–72PubMedCrossRef
14.
Zurück zum Zitat van Rooijen N, van Nieuwmegen R (1984) Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. Cell Tissue Res 238:355–358PubMedCrossRef van Rooijen N, van Nieuwmegen R (1984) Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. Cell Tissue Res 238:355–358PubMedCrossRef
15.
Zurück zum Zitat Mönkkönen J, Taskinen M, Auriola SO, Urtti A (1994) Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro. J Drug Target 2:299–308PubMedCrossRef Mönkkönen J, Taskinen M, Auriola SO, Urtti A (1994) Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro. J Drug Target 2:299–308PubMedCrossRef
16.
Zurück zum Zitat Pennanen N, Lapinjoki S, Urtti A, Mönkkönen J (1995) Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 12:916–922PubMedCrossRef Pennanen N, Lapinjoki S, Urtti A, Mönkkönen J (1995) Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 12:916–922PubMedCrossRef
17.
Zurück zum Zitat Kramsch DM, Chan CT (1978) The effect of agents interfering with soft tissue calcification and cell proliferation on calcific fibrous-fatty plaques in rabbits. Circ Res 42:562–571PubMed Kramsch DM, Chan CT (1978) The effect of agents interfering with soft tissue calcification and cell proliferation on calcific fibrous-fatty plaques in rabbits. Circ Res 42:562–571PubMed
18.
Zurück zum Zitat Daoud AS, Frank AS, Jarmolych J, Fritz KE (1987) The effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on necrosis of atherosclerotic lesion. Atherosclerosis 67:41–48PubMedCrossRef Daoud AS, Frank AS, Jarmolych J, Fritz KE (1987) The effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on necrosis of atherosclerotic lesion. Atherosclerosis 67:41–48PubMedCrossRef
19.
Zurück zum Zitat Ariyoshi T, Eishi K, Sakamoto I, Matsukuma S, Odate T (2006) Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Invest 26:215–222 Ariyoshi T, Eishi K, Sakamoto I, Matsukuma S, Odate T (2006) Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Invest 26:215–222
20.
Zurück zum Zitat Rodan GA (1998) Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 38:375–388PubMedCrossRef Rodan GA (1998) Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 38:375–388PubMedCrossRef
22.
Zurück zum Zitat Robertson WG (1973) Factors affecting the precipitation of calcium phosphate in vitro. Calcif Tissue Res 11:311–322PubMedCrossRef Robertson WG (1973) Factors affecting the precipitation of calcium phosphate in vitro. Calcif Tissue Res 11:311–322PubMedCrossRef
23.
Zurück zum Zitat Francis MD, Russell RG, Fleisch H (1969) Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165:1264–1266PubMedCrossRef Francis MD, Russell RG, Fleisch H (1969) Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165:1264–1266PubMedCrossRef
24.
Zurück zum Zitat Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P (1983) Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 35:87–99PubMedCrossRef Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P (1983) Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 35:87–99PubMedCrossRef
25.
Zurück zum Zitat Jono S, Nishizawa Y, Shioi A, Morii H (1997) Parathyroid hormone-related peptide as a local regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17:1135–1142PubMedCrossRef Jono S, Nishizawa Y, Shioi A, Morii H (1997) Parathyroid hormone-related peptide as a local regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17:1135–1142PubMedCrossRef
26.
Zurück zum Zitat Giuliani N, Pedrazzoni M, Passeri G, Girasole G (1998) Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 27:38–41PubMedCrossRef Giuliani N, Pedrazzoni M, Passeri G, Girasole G (1998) Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 27:38–41PubMedCrossRef
Metadaten
Titel
Marked improvement of calcinosis in adult dermatomyositis with etidronate therapy
verfasst von
Hiroko Mori
Yosuke Okada
Kunihiro Yamaoka
Kazuyoshi Saito
Yoshiya Tanaka
Publikationsdatum
01.01.2012
Verlag
Springer Japan
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 1/2012
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-011-0289-1

Weitere Artikel der Ausgabe 1/2012

Journal of Bone and Mineral Metabolism 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.